Last reviewed · How we verify
NCT00923026
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
trial in Melanoma in 1,150 participants. Enrolling by invitation.
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 1,150 |
| Start date | 15 June 2009 |
| Sites | 1 location across United States |
Conditions studied
- Melanoma — all drugs for Melanoma →
- Adenocarcinoma — all drugs for Adenocarcinoma →
- Carcinoma NOS — all drugs for Carcinoma NOS →
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Sponsor
National Cancer Institute (NCI)
Who can join
18 and older, any sex, with Melanoma or Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow participants to be followed for up to 15 years following treatment on an NCI Surgery Branch Gene Therapy Trial as required by the FDA. Eligibility: Participants must have been enrolled on an NCI Surgery Branch Gene Therapy Protocol Design Participants will be followed with a physical examination and blood tests for up to 15 years as required by the FDA ...
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM, Sherry RM, Yang JC, Goff SL, et al · · 2020 · cited 234× · PMID 33021872 · DOI 10.1200/jco.20.01467 -
Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up.
Gavrilova T, McIntyre L, Goff SL, Yang JC, et al · · 2025 · cited 1× · PMID 40690752 · DOI 10.1182/bloodadvances.2025016504
Verify or expand the search:
- PubMed search for NCT00923026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
- NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00923026 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00923026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing